ATE316965T1 - Kondensierte heteroaromatische glucokinaseaktivatoren - Google Patents

Kondensierte heteroaromatische glucokinaseaktivatoren

Info

Publication number
ATE316965T1
ATE316965T1 AT01999565T AT01999565T ATE316965T1 AT E316965 T1 ATE316965 T1 AT E316965T1 AT 01999565 T AT01999565 T AT 01999565T AT 01999565 T AT01999565 T AT 01999565T AT E316965 T1 ATE316965 T1 AT E316965T1
Authority
AT
Austria
Prior art keywords
condensed heteroaromatic
glucocinase
activators
glucocinase activators
heteroaromatic
Prior art date
Application number
AT01999565T
Other languages
English (en)
Inventor
Wendy Lea Corbett
Joseph Samuel Grimbsy
Nancy-Ellen Haynes
Robert Francis Kester
Paige Erin Mahaney
Ramakanth Sarabu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE316965T1 publication Critical patent/ATE316965T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT01999565T 2000-12-06 2001-11-28 Kondensierte heteroaromatische glucokinaseaktivatoren ATE316965T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25163700P 2000-12-06 2000-12-06

Publications (1)

Publication Number Publication Date
ATE316965T1 true ATE316965T1 (de) 2006-02-15

Family

ID=22952803

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01999565T ATE316965T1 (de) 2000-12-06 2001-11-28 Kondensierte heteroaromatische glucokinaseaktivatoren

Country Status (21)

Country Link
US (3) US6441184B1 (de)
EP (1) EP1341774B1 (de)
JP (1) JP4109111B2 (de)
KR (1) KR100545431B1 (de)
CN (1) CN1226294C (de)
AR (1) AR031627A1 (de)
AT (1) ATE316965T1 (de)
AU (2) AU2190202A (de)
BR (1) BR0115999A (de)
CA (1) CA2429642C (de)
DE (1) DE60117059T2 (de)
DK (1) DK1341774T3 (de)
ES (1) ES2256340T3 (de)
GT (1) GT200100243A (de)
MX (1) MXPA03005119A (de)
PA (1) PA8534301A1 (de)
PE (1) PE20020753A1 (de)
PT (1) PT1341774E (de)
UY (1) UY27055A1 (de)
WO (1) WO2002046173A1 (de)
ZA (1) ZA200303748B (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
US6775812B2 (en) * 2002-07-17 2004-08-10 Hewlett-Packard Development Company, L.P. Layout design process and system for providing bypass capacitance and compliant density in an integrated circuit
JP2006509774A (ja) * 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト ２型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換（チアゾール−２−イル）−アミドまたはスルホンアミド
CA2499329C (en) 2002-10-03 2009-04-21 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
GB0226931D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
JP4621198B2 (ja) * 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ（シクロ）置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
WO2005000301A1 (en) * 2003-06-20 2005-01-06 F. Hoffmann-La Roche Ag 2-aminobenzothiazoles as cb1 receptor inverse agonists
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
ATE426597T1 (de) * 2004-02-18 2009-04-15 Astrazeneca Ab Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
BRPI0507734A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
EP1737870A1 (de) * 2004-04-02 2007-01-03 Novartis AG Thiazolopyridinderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zur behandlung von durch glucokinase vermittelten leiden
CN1960995B (zh) * 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
AU2005235798A1 (en) * 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
KR20070085371A (ko) 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
BRPI0517232A (pt) * 2004-11-02 2008-10-07 Banyu Pharma Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
DE102005012872A1 (de) * 2005-03-19 2006-09-28 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1891069A1 (de) * 2005-05-24 2008-02-27 AstraZeneca AB 2-phenylsubstituierte imidazol[4,5b]pyridin/pyrazin- und purinderivate als glucokinasemodulatoren
TW200714597A (en) * 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
EP2027113A1 (de) * 2005-07-09 2009-02-25 AstraZeneca AB Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
JP2009500442A (ja) * 2005-07-09 2009-01-08 アストラゼネカ アクチボラグ ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
US7642259B2 (en) * 2005-07-09 2010-01-05 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
US7994331B2 (en) 2005-07-13 2011-08-09 Msd K.K. Heterocycle-substituted benzimidazole derivative
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
TW200738621A (en) * 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
AT503354B1 (de) * 2006-02-22 2008-07-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von 3,4-disubstituierten phenylessigsäuren, sowie neue zwischenverbindungen
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CA2657566A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
TW200833339A (en) * 2006-12-21 2008-08-16 Astrazeneca Ab Novel crystalline compound
TW200831081A (en) * 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
CN101687800B (zh) * 2007-03-07 2012-03-21 杏林制药株式会社 葡糖激酶活化物质
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
AU2009205070A1 (en) * 2008-01-18 2009-07-23 Astellas Pharma Inc. Phenyl acetamide derivative
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
MY163114A (en) 2008-04-28 2017-08-15 Kyorin Seiyaku Kk Cyclopentylacrylamide derivative
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
JP5937353B2 (ja) * 2008-08-19 2016-06-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 冷感−メントール受容体拮抗剤
GEP20135793B (en) 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
ES2489297B1 (es) 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
EP2878339A1 (de) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3-Antagonisten
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
DK3294713T5 (da) 2015-05-15 2021-05-31 Aurigene Discovery Tech Ltd Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도
CN118496217A (zh) 2018-11-20 2024-08-16 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
EP4161640A4 (de) 2020-06-08 2024-01-17 vTv Therapeutics LLC Salze oder cokristalle von {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido)-thiazol-5-ylsulfanyl}-essigsäure und verwendungen davon

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840550A (en) * 1971-05-24 1974-10-08 Ciba Geigy Corp Certain 6-isothiocyanobenzothiazoles
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
HRP20010688B1 (en) * 1999-03-29 2008-10-31 F. Hoffmann - La Roche Ag Glucokinase activators

Also Published As

Publication number Publication date
CN1226294C (zh) 2005-11-09
US6448399B1 (en) 2002-09-10
DE60117059T2 (de) 2006-10-26
GT200100243A (es) 2002-06-04
CN1476438A (zh) 2004-02-18
PA8534301A1 (es) 2002-08-26
KR100545431B1 (ko) 2006-01-24
US20020107396A1 (en) 2002-08-08
KR20030068555A (ko) 2003-08-21
PE20020753A1 (es) 2002-08-27
CA2429642C (en) 2007-11-20
ZA200303748B (en) 2004-08-16
EP1341774B1 (de) 2006-02-01
JP4109111B2 (ja) 2008-07-02
UY27055A1 (es) 2002-07-31
CA2429642A1 (en) 2002-06-13
DE60117059D1 (de) 2006-04-13
MXPA03005119A (es) 2004-10-15
US6441184B1 (en) 2002-08-27
EP1341774A1 (de) 2003-09-10
US20020103199A1 (en) 2002-08-01
AU2002221902B2 (en) 2006-11-23
PT1341774E (pt) 2006-05-31
WO2002046173A1 (en) 2002-06-13
AU2190202A (en) 2002-06-18
US20020103241A1 (en) 2002-08-01
JP2004517087A (ja) 2004-06-10
AR031627A1 (es) 2003-09-24
BR0115999A (pt) 2003-09-30
ES2256340T3 (es) 2006-07-16
DK1341774T3 (da) 2006-06-12
US6545155B2 (en) 2003-04-08

Similar Documents

Publication Publication Date Title
DE60117059D1 (de) Kondensierte heteroaromatische glucokinaseaktivatoren
DE60134470D1 (de) Para-amin substituierte phenylamid glukokinase activatoren
DE60108108D1 (de) Heteroaromatische alkynylphenyl-verbindungen als glukokinase-aktivatoren
NO20030845L (no) Utvalgte kondenserte pyrrolokarbazoler
DK1311504T3 (da) Tetrazolyl-phenylacetamid-glucokinase-aktivatorer
DK1280801T3 (da) Hydantoinholdige glucokinaseaktivatorer
NO20032585D0 (no) ABCA-1 forhöyende forbindelser
DK1226127T3 (da) Substituerede phenylsulfamoylcarboxamider
DE60126873D1 (de) PLL-Schaltung
DK1303496T3 (da) Pyrimidinderivater
NO20032615D0 (no) Insektstoppende klesplagg
DE60114153D1 (de) Substituierte arylpyrazine
AR028393A1 (es) Iminoazidas substituidas
NO20030917L (no) Anvendelse
DE60125415D1 (de) Formeinsatz
ATE388040T1 (de) Träger
ATE365721T1 (de) Substituierte benzoylcyclohexenone
AR028302A1 (es) Feniluracilos substituidos
NO20032291D0 (no) Pyrimidinderivater
DK1322651T3 (da) Bicykliske, heteroaromatiske forbindelser
ATA4432000A (de) Streugerät
DE60104363D1 (de) Terphenylverbindungen
DE50106006D1 (de) Streugerät
ATA2372000A (de) Wäschetrockner
FR2817889B1 (fr) Coffrage

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1341774

Country of ref document: EP

REN Ceased due to non-payment of the annual fee